GlassScriptPhysician profile
Daniel Thomas Franc
NPI 1548589799
$9,029.73
in general payments reported to CMS, 2019-2025
50 companies · $1,765 in 2025
The $1,765 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,399 · 2020: $496 · 2021: $1,563 · 2022: $1,385 · 2023: $1,530 · 2024: $891 · 2025: $1,765.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,186.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,195.62 | 2021-2025 | |
| Merz Pharmaceuticals, LLC | $679.11 | 2021-2025 | Xeomin, Inbrija, Ampyra |
| Biogen, INC. | $550.44 | 2019-2025 | Leqembi |
| Lilly USA, LLC | $486.19 | 2020-2024 | Amyvid, Kisunla |
| Ucb, INC. | $471.46 | 2019-2025 | Zilbrysq, Rystiggo |
| Avanir Pharmaceuticals, INC. | $324.95 | 2019-2022 | |
| Allergan, INC. | $301.25 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $279.97 | 2021-2025 | |
| Amgen INC. | $267.96 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $263.26 | 2019-2024 | Austedo Xr |
| Pfizer INC. | $226.03 | 2021-2025 | |
| Lundbeck LLC | $223.15 | 2019-2025 | Vyepti |
| Biohaven Pharmaceutical Holding Company LTD. | $217.77 | 2022 | |
| Csl Behring | $200.61 | 2019-2021 | |
| Merz North America, INC. | $185.63 | 2019-2020 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Franc listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.